Enanta Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $381.8M
- Price
- $13.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.81%
- Volume
- 193.0K
About
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Quick stats
Shares outstanding29.1M
Computed float27.4M
Float / shares94.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001177648
Websitehttps://www.enanta.com
AI Summary
AI-generated1/15
standardmixedearnings
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Enanta reported fiscal Q3 revenue of $14.4 million, a decline from $18.3 million in the prior year due to lower sales of AbbVie’s HCV regimen MAVYRET, while posting a net loss of $19.5 million or $0.67 per share.
The company remains on track with its pipeline, initiating dosing in the LOTUS Phase 2b pediatric RSV trial and preparing to launch the RESOLVE registrational trial in high-risk adults in the fourth quarter.
Management confirmed a strong balance sheet with $211.5 million in cash and marketable securities, which is expected to fund operations into fiscal 2029.
In legal updates, the company noted that the Federal Circuit affirmed the invalidity of a patent against Pfizer in June, though a petition for rehearing has been filed with a UPC hearing scheduled for late September.
Red flags
- Federal Circuit affirmed invalidity of patent against Pfizer, removing potential upside from that litigation
- Q3 revenue declined 22% year-over-year driven by waning HCV sales